Skip to main content
CJC-1295 Online

An online reading room for the CJC-1295 research record — the GHRH analog, its DAC variant, and the pharmacokinetics that separate them.

06 / what the guide can tell you

CJC-1295 Online Helps You Read the Evidence

Hormone tests measured changes in blood, without proving benefits for health. CJC-1295 findings come from published studies checked by other scientists. The guide explains what those tests leave unanswered.

The Guide Explains Findings Without Assessing Your Health

CJC-1295 studies measured hormone levels and time left in blood. CJC-1295 Online covers the findings about linked and unlinked forms. Study amounts and brief unwanted effects are described with their sources. A death stopped the 2006 stage 2 trial of possible benefit. That stage follows early safety tests. Measured changes leave health questions open.

These study pages can't assess your health or prescribe your care.

There is no clinic or medical staff behind the guide. Treatment advice and prescription services are not provided here. No pharmacy makes medicines here; the guide makes and ships nothing. Published science and source links are what these pages offer.

The closing words describe a companion guide to medical studies. That is what 'journal supplement' means on this site. Edition number 01 identifies the guide, without measuring evidence strength. The number doesn't strengthen the evidence.

The Studies Name Different People, Animals, and Questions

In 2006, healthy adults underwent stage 1 safety testing by Teichman [3]. In 2006, Ionescu measured raised hormone levels with unchanged bursts [4]. In 2006, Alba studied how mice grew without the starting hormone [8]. In 2005, Jetté first identified CJC-1295 in a study paper [1]. In 1994, Coy tested a change that slowed hormone breakdown [2]. In 1998, Raun found strong growth hormone release from ipamorelin in animals. Other hormones, including the stress hormone cortisol, didn't rise greatly [12]. The stopped stage 2 trial is listed on ClinicalTrials.gov [9]. In 2006, aidsmap reported that trial's halt [5]. A 2024 review examined growth hormone, the liver hormone, and insulin [15]. Insulin helps control your blood sugar.

A mouse's growth and a person's blood test answer different questions.

Lasting human safety and health benefits remain unknown. Completed stage 2 testing hasn't supplied that proof. Direct effects on testosterone, a sex hormone, haven't been shown. Each figure points to its supporting paper. You can distinguish measured changes from unproven benefits. Growth in mice can't prove health gains for you.

The Studies Name Different People, Animals, and Questions

Approval Has Not Followed the Pharmacy Requests

Neither the FDA nor other drug regulators have approved CJC-1295 for treatment [16]. In the United States, the substance is a drug under study. In July 2006, a death stopped ConjuChem's stage 2 benefit trial. The CJC-1295 trial concerned abnormal fat changes, and company development ended [5][9]. FDA's page current as of April 22, 2026 lists withdrawn pharmacy requests. The requests concerned CJC-1295 and ipamorelin acetate. Acetate names the salt form of ipamorelin. The safety warnings remain. Ipamorelin acetate stays in Category 2, FDA's group flagged for safety concerns. This listing covers businesses making large batches for clinics or pharmacies. That safety category gives those businesses no permission to prepare the substance. Separate rules cover pharmacies mixing medicine for one patient's prescription. FDA hasn't clarified what withdrawal allows those pharmacies to prepare [16]. Sports rules ban CJC-1295 both during contests and between contests [7].

Withdrawing a request doesn't establish safety or grant treatment approval.

Tesamorelin differs in the makeup of its protein-building chain. Tesamorelin also copies the body's starting hormone for growth hormone release. Among substances of that kind, tesamorelin alone has FDA approval [17]. A different substance's approval doesn't give this substance treatment approval.

Your Doctor Can Relate the Findings to Your Health

No doctor or clinical team works for this guide. The guide offers no pharmacy service or video doctor visits. There are no products or prices here. The name's word 'online' refers to the guide you are reading. These pages explain what researchers found, without supplying medical care.

Your own doctor handles questions about treatment and prescriptions.

Your own health assessment takes more than a study summary. The guide doesn't present study findings as a personal treatment decision.